{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T22:42:37Z","timestamp":1786747357727,"version":"build-2736575974"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23 DK113252"],"award-info":[{"award-number":["K23 DK113252"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Doris Duke Foundation"},{"name":"Boston University School of Medicine Department of Medicine Career Investment Awar"},{"name":"Boston University Clinical Translational Science Institute","award":["UL1 TR001430"],"award-info":[{"award-number":["UL1 TR001430"]}]},{"DOI":"10.13039\/100000066","name":"NIEHS","doi-asserted-by":"publisher","award":["5P42ES010337"],"award-info":[{"award-number":["5P42ES010337"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"publisher","award":["5UL1TR001442"],"award-info":[{"award-number":["5UL1TR001442"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["R01DK106419"],"award-info":[{"award-number":["R01DK106419"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["P30DK120515"],"award-info":[{"award-number":["P30DK120515"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["R01DK121378"],"award-info":[{"award-number":["R01DK121378"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DOD PRCRP","award":["W81XWH-18-2-0026"],"award-info":[{"award-number":["W81XWH-18-2-0026"]}]},{"name":"Echosens Corporation"},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.metabol.2020.154259","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T11:38:27Z","timestamp":1588678707000},"page":"154259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"S","title":["Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease"],"prefix":"10.1016","volume":"111","author":[{"given":"Michelle T.","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanil","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2020.154259_bb0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0010","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","author":"Loomba","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0015","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.metabol.2020.154259_bb0025","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology."},{"key":"10.1016\/j.metabol.2020.154259_bb0030","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.29546","article-title":"Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study","volume":"67","author":"Allen","year":"2018","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0035","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - a longitudinal cohort study","volume":"71","author":"Allen","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0040","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jhep.2016.09.022","article-title":"Bi-directional analysis between fatty liver and cardiovascular disease risk factors","volume":"66","author":"Ma","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0045","doi-asserted-by":"crossref","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic review and meta-analysis","author":"Dulai","year":"2017","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0050","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/hep.30672","article-title":"Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the liver forum","volume":"70","author":"Cheung","year":"2019","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0055","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1053\/j.gastro.2014.09.047","article-title":"Liver biopsy for the selection of patients with nonalcoholic steatohepatitis for clinical trials","volume":"148","author":"Rowe","year":"2015","journal-title":"Gastroenterology."},{"key":"10.1016\/j.metabol.2020.154259_bb0060","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C","volume":"38","author":"Bedossa","year":"2003","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0065","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.cgh.2017.08.024","article-title":"Noninvasive tests do not accurately differentiate nonalcoholic steatohepatitis from simple steatosis: a systematic review and meta-analysis","volume":"16","author":"Verhaegh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0070","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/liv.12226","article-title":"Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)","volume":"33","author":"Verma","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2020.154259_bb0075","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2036.2008.03896.x","article-title":"Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels","volume":"29","author":"Wong","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2020.154259_bb0080","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/apt.12569","article-title":"Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease\u2014the role of transient elastography and plasma cytokeratin-18 fragments","volume":"39","author":"Kwok","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2020.154259_bb0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hep.28776","article-title":"Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease","volume":"65","author":"Ajmera","year":"2017","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0090","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/hc3301.092803","article-title":"Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition","volume":"104","author":"Kaikita","year":"2001","journal-title":"Circulation."},{"key":"10.1016\/j.metabol.2020.154259_bb0095","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.2337\/dc07-0109","article-title":"Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis","volume":"30","author":"Targher","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2020.154259_bb0100","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1194\/jlr.M007096","article-title":"Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"51","author":"Feldstein","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2020.154259_bb0105","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1586\/egh.09.32","article-title":"Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal","volume":"3","author":"Alkhouri","year":"2009","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0110","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1194\/jlr.P055640","article-title":"Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis","volume":"56","author":"Loomba","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2020.154259_bb0115","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/hep.21763","article-title":"A lipidomic analysis of nonalcoholic fatty liver disease","volume":"46","author":"Puri","year":"2007","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0120","doi-asserted-by":"crossref","first-page":"154005","DOI":"10.1016\/j.metabol.2019.154005","article-title":"Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study","volume":"101","author":"Perakakis","year":"2019","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2020.154259_bb0125","doi-asserted-by":"crossref","first-page":"153994","DOI":"10.1016\/j.metabol.2019.153994","article-title":"Fibroblast growth factor 21 in non-alcoholic fatty liver disease","volume":"101","author":"Tucker","year":"2019","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2020.154259_bb0130","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.metabol.2020.154259_bb0135","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cgh.2016.09.150","article-title":"Weight loss decreases magnetic resonance elastography estimated liver stiffness in nonalcoholic fatty liver disease","volume":"15","author":"Patel","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0140","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jhep.2011.12.025","article-title":"Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers","volume":"56","author":"Shen","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0145","doi-asserted-by":"crossref","first-page":"36401","DOI":"10.1074\/jbc.M110.172866","article-title":"Transcriptional repressor E4-binding protein 4 (E4BP4) regulates metabolic hormone fibroblast growth factor 21 (FGF21) during circadian cycles and feeding","volume":"285","author":"Tong","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2020.154259_bb0150","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1373\/clinchem.2010.155184","article-title":"Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans","volume":"57","author":"Yu","year":"2011","journal-title":"Clin Chem"},{"key":"10.1016\/j.metabol.2020.154259_bb0155","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH - current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0160","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0165","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0170","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0175","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers","volume":"68","author":"Vilar-Gomez","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0180","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.gastro.2019.11.024","article-title":"Are noninvasive scoring systems for persons with chronic liver disease ready for prime time?","volume":"158","author":"Younossi","year":"2020","journal-title":"Gastroenterology."},{"key":"10.1016\/j.metabol.2020.154259_bb0185","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.metabol.2020.154259_bb0190","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants","volume":"17","author":"Hsu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0195","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"152","author":"Park","year":"2017","journal-title":"Gastroenterology."},{"key":"10.1016\/j.metabol.2020.154259_bb0200","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0205","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/hep.25993","article-title":"Determination of reliability criteria for liver stiffness evaluation by transient elastography","volume":"57","author":"Boursier","year":"2013","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0210","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/hep.29489","article-title":"Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease","volume":"67","author":"Vuppalanchi","year":"2018","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0215","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","article-title":"Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0220","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nrgastro.2018.10","article-title":"Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD","volume":"15","author":"Tapper","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0225","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/ajg.2012.331","article-title":"Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease","volume":"107","author":"Wong","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.metabol.2020.154259_bb0230","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cgh.2014.04.039","article-title":"FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice","volume":"13","author":"Tapper","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0235","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/hep.25936","article-title":"Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study","volume":"56","author":"Ferraioli","year":"2012","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0240","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.3748\/wjg.15.5525","article-title":"Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis","volume":"15","author":"Fierbinteanu-Braticevici","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.metabol.2020.154259_bb0245","doi-asserted-by":"crossref","first-page":"167","DOI":"10.15403\/jgld.2014.1121.252.lsf","article-title":"Liver stiffness evaluation by transient elastography in type 2 diabetes mellitus patients with ultrasound-proven steatosis","volume":"25","author":"Sporea","year":"2016","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.metabol.2020.154259_bb0250","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1002\/hep.28394","article-title":"Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy","volume":"63","author":"Cassinotto","year":"2016","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jmri.24084","article-title":"Magnetic resonance elastography of liver in healthy Asians: normal liver stiffness quantification and reproducibility assessment","volume":"39","author":"Venkatesh","year":"2014","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.metabol.2020.154259_bb0260","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00330-015-3949-z","article-title":"Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis","volume":"26","author":"Singh","year":"2016","journal-title":"Eur Radiol"},{"key":"10.1016\/j.metabol.2020.154259_bb0265","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1148\/radiol.2016160685","article-title":"Diagnostic performance of MR elastography and vibration-controlled transient elastography in the detection of hepatic fibrosis in patients with severe to morbid obesity","volume":"283","author":"Chen","year":"2017","journal-title":"Radiology."},{"key":"10.1016\/j.metabol.2020.154259_bb0270","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1148\/radiol.2016160863","article-title":"Technical failure of MR elastography examinations of the liver: experience from a large single-center study","volume":"284","author":"Wagner","year":"2017","journal-title":"Radiology."},{"key":"10.1016\/j.metabol.2020.154259_bb0275","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography","volume":"150","author":"Imajo","year":"2016","journal-title":"Gastroenterology."},{"key":"10.1016\/j.metabol.2020.154259_bb0280","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1055\/s-0035-1571276","article-title":"Targeting dysbiosis for the treatment of liver disease","volume":"36","author":"Anand","year":"2016","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.metabol.2020.154259_bb0285","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0290","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/hep.28829","article-title":"Changes in blood microbiota profiles associated with liver fibrosis in obese patients: a pilot analysis","volume":"64","author":"Lelouvier","year":"2016","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0295","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2020.154259_bb0300","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41591-018-0061-3","article-title":"Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women","volume":"24","author":"Hoyles","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2020.154259_bb0305","doi-asserted-by":"crossref","DOI":"10.1002\/hep.29892","article-title":"Novel link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD","author":"Caussy","year":"2018","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0310","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s41467-019-09455-9","article-title":"A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease","volume":"10","author":"Caussy","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2020.154259_bb0315","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.cgh.2014.05.010","article-title":"Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease","volume":"12","author":"Vuppalanchi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0320","article-title":"Alanine aminotransferase as a monitoring biomarker in children with nonalcoholic fatty liver disease: a secondary analysis using TONIC trial data","volume":"5","author":"Arsik","year":"2018","journal-title":"Children (Basel)"},{"key":"10.1016\/j.metabol.2020.154259_bb0325","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1111\/liv.13480","article-title":"Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH","volume":"37","author":"Vilar-Gomez","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2020.154259_bb0330","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/liv.13974","article-title":"Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis","volume":"39","author":"Chalasani","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2020.154259_bb0335","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jhep.2018.09.024","article-title":"Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib","volume":"70","author":"Jayakumar","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0340","first-page":"1120A","article-title":"Prospective validation of the enhanced liver fibrosis (ELF) test for the prediction of disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis","volume":"66","author":"Harrison","year":"2017","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0345","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.cgh.2014.07.037","article-title":"Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases","volume":"13","author":"Nascimbeni","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0350","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10238-018-0501-x","article-title":"Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment","volume":"18","author":"Wu","year":"2018","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.metabol.2020.154259_bb0355","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1053\/j.gastro.2018.04.014","article-title":"Magnetic resonance imaging proton density fat fraction associates with progression of fibrosis in patients with nonalcoholic fatty liver disease","volume":"155","author":"Ajmera","year":"2018","journal-title":"Gastroenterology."},{"key":"10.1016\/j.metabol.2020.154259_bb0360","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/jmri.25006","article-title":"Accuracy and the effect of possible subject-based confounders of magnitude-based MRI for estimating hepatic proton density fat fraction in adults, using MR spectroscopy as reference","volume":"43","author":"Heba","year":"2016","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.metabol.2020.154259_bb0365","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1053\/j.gastro.2017.06.005","article-title":"Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis","volume":"153","author":"Middleton","year":"2017","journal-title":"Gastroenterology."},{"key":"10.1016\/j.metabol.2020.154259_bb0370","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/hep.29596","article-title":"Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease","volume":"67","author":"Middleton","year":"2018","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0375","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","article-title":"Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)","volume":"61","author":"Loomba","year":"2015","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0380","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/hep.26455","article-title":"Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials","volume":"58","author":"Noureddin","year":"2013","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(19)30338-8","article-title":"Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial","author":"Stanley","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.metabol.2020.154259_bb0390","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/hep.30782","article-title":"Report on the AASLD\/EASL joint workshop on clinical trial endpoints in NAFLD","volume":"70","author":"Rinella","year":"2019","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0395","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1177\/1756283X16656735","article-title":"Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis","volume":"9","author":"Patel","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.metabol.2020.154259_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","author":"Harrison","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.metabol.2020.154259_bb0405","article-title":"Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in NAFLD","author":"Ajmera","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2020.154259_bb0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128774","article-title":"Prognostic value of non-invasive fibrosis and steatosis tools, hepatic venous pressure gradient (HVPG) and histology in nonalcoholic steatohepatitis","volume":"10","author":"Sebastiani","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2020.154259_bb0415","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1136\/gut.2009.203166","article-title":"Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease","volume":"59","author":"Parkes","year":"2010","journal-title":"Gut."},{"key":"10.1016\/j.metabol.2020.154259_bb0420","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jhep.2016.04.023","article-title":"Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease","volume":"65","author":"Boursier","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0425","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.cgh.2013.07.034","article-title":"Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"11","author":"Singh","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2020.154259_bb0430","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis","volume":"56","author":"Corpechot","year":"2012","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2020.154259_bb0435","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1111\/liv.12846","article-title":"Evaluation of portal hypertension by real-time shear wave elastography in cirrhotic patients","volume":"35","author":"Kim","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2020.154259_bb0440","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1148\/radiol.14140008","article-title":"Shear-wave elastography: a noninvasive tool for monitoring changing hepatic venous pressure gradients in patients with cirrhosis","volume":"273","author":"Choi","year":"2014","journal-title":"Radiology."}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049520301232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049520301232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:24:33Z","timestamp":1758428673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049520301232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":88,"alternative-id":["S0026049520301232"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2020.154259","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2020.154259","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154259"}}